| Name | Title | Contact Details |
|---|
The FidoCure® team is committed to introducing the therapies that have been successfully used to treat humans with cancer into the world of veterinary medicine. Currently, cancer care for dogs lags behind human cancer care by about 20 years. Our goal is to improve the outcome for canine cancer patients. We are the first and only company to offer the information needed to work with your veterinarian on targeted medicines for dogs with cancer.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.
Beta Bionics is proud to be a Massachusetts public benefit corporation.
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients. In addition, MannKind is applying our novel technologies and services to support partner development efforts.